Abstract | OBJECTIVES: METHODS: Data from all UC patients receiving infliximab at four institutions were analyzed. Disease activity was determined by the Disease Activity Index. RESULTS: A total of 27 patients with active UC received inpatient (37%) and outpatient (63%) infliximab as single (52%) or multiple (two to 15) infusions (48%). Twelve patients (44%) achieved remission and six patients (22%) had partial response. Nine patients had no response; five subsequently underwent total colectomy. The median time to achieve response and remission was 4 days and the median duration 8 wk. Nine of the 18 patients who responded experienced 19 relapses; 18 of these relapses (95%) were successfully treated with repeat infusions. Steroid-refractory patients were less likely to respond to infliximab therapy than were steroid-responsive patients (33% vs 83%; p = 0.026). No other factors were predictive of response to infliximab. Two patients developed serious adverse events, including death in one case. CONCLUSIONS: Preliminary evidence suggest effectiveness of infliximab in the treatment of UC, including medically refractory severe disease. Individuals who are refractory to corticosteroids, however, may be unlikely to respond to infliximab. A randomized controlled trial is necessary to further investigate the efficacy of infliximab in patients with UC.
|
Authors | Chinyu Su, Bruce A Salzberg, James D Lewis, Julius J Deren, Asher Kornbluth, David A Katzka, Robert B Stein, Douglas R Adler, Gary R Lichtenstein |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 97
Issue 10
Pg. 2577-84
(Oct 2002)
ISSN: 0002-9270 [Print] United States |
PMID | 12385442
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- Infliximab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Colitis, Ulcerative
(drug therapy)
- Female
- Humans
- Infliximab
- Male
- Middle Aged
- Remission Induction
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|